Did you know?

ChinaBio^® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

Free Report

State of China Life Science 2022

Free Content

Week in Review

In My Opinion

Free Articles

Subscriber Content

Sihuan Pharma Approved to Start China Trials of Third-Gen EGFR Inhibitor

publication date: May 29, 2019

Sihuan Pharma of Beijing, China's largest cardio-cerebral vascular drug company, announced approval for China clinical trials of its third-gen EGFR inhibitor, XZP-5809, a Category 1 innovative drug. Sihuan said XZP-5809 is an oral drug with strong targeting ability, an innovative structure, an established mechanism and irreversible binding to EGFR. In pre-clinical tests, it demonstrated better selection with higher activity against gene-mutation EGFR and lower activity against wild-type EGFR, which Sihuan believes will result in a better safety profile. More details....

Stock Symbol: (HK: 0460)

Share this with colleagues:

This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

Click here to join.